← 返回

胰腺导管腺癌中肿瘤浸润 NK 细胞的特征分析

英文原题:Tumor-Infiltrating Natural Killer Cell Characterization in Pancreatic Ductal Adenocarcinoma.

查看英文原题

Tumor-Infiltrating Natural Killer Cell Characterization in Pancreatic Ductal Adenocarcinoma.

PubMed 2026/04/28(内容时间) Cells Q2 · IF 6(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

胰腺导管腺癌(PDAC)死亡率高、预后差,目前有效治疗有限。来自TIL(肿瘤浸润淋巴细胞)的自然杀伤(NK)细胞能够迁移至肿瘤微环境(TME),且安全性良好,因此在癌症治疗中具有潜力。

然而,扩增患者来源且有功能的 NK 细胞仍具挑战。本研究培养、扩增并表征了从 PDAC 肿瘤中心和边缘区域分离的 TIL-NK 细胞。研究在 IL-2、IL-15 和 IL-12 刺激下,对患者来源外周血单个核细胞(PBMC)和 TIL 进行体外培养,并在手术时及培养 12 天后评估免疫表型、扩增速率和活化情况,以表征 NK 细胞表型和功能。

研究发现 TME 内 NK 细胞浸润分布存在差异,肿瘤边缘的 NK 细胞数量高于中心区域。多数 NK 细胞呈细胞毒表型(CD56⁺CD16⁺)。与 PBMC 相比,TIL-NK 细胞活化标志物表达较低,但肿瘤浸润和扩增能力更强,尤其是从肿瘤中心分离的细胞。

值得注意的是,细胞因子刺激改善了患者来源 NK 细胞的活化和细胞毒性表型。这项先导研究提供了关于 PDAC 患者 TIL-NK 细胞的初步但重要见解,为开发实体瘤 NK 细胞免疫疗法奠定基础。

展开英文摘要原文

Pancreatic ductal adenocarcinoma (PDAC) has high mortality rates, poor prognosis, and currently limited effective treatments. Natural killer (NK) cells from tumor-infiltrating lymphocytes (TIL) show promise for cancer treatment due to their ability to migrate to the tumor microenvironment (TME) and safe profile.

However, expanding functional patient-derived NK cells remains challenging.

Here, we cultured, expanded, and characterized TIL-NK cells isolated from central and peripheral tumor regions from PDAC. Ex vivo patient-derived PBMCs and TIL were cultured under IL-2, IL-15, and IL-12 stimulation. Phenotypical and functional NK cell characterization was assessed at the time of surgery and after 12 days of culture evaluating immunophenotype, expansion rate, and activation.

A distinct distribution of NK cell infiltration was observed within the TME, with higher NK cell numbers in the periphery of the tumor compared to the central area. Most NK cells displayed a cytotoxic phenotype (CD56 + CD16 + ). Compared to PBMCs, TIL-NK cells expressed lower activation markers but superior tumor infiltration and expansion rates, particularly those isolated from the central regions.

Notably, cytokine stimulation improved patient-derived NK cell activation and cytotoxic profile. This pilot study provides preliminary but critical insights regarding TIL-NK cells from PDAC patients, laying groundwork for developing NK cell-based immunotherapies for solid tumors.

论文信息

作者
Maia A、Calá H、de Sousa E、Lérias JR、Gorgulho CM、António PA、Kamiki J、Ligeiro D
单位
Molecular and Experimental Pathology Laboratory, Champalimaud Centre for the Unknown, Champalimaud Foundation, 1400-038 Lisbon, Portugal.Portugal
期刊
Cells2026 Apr 28
原文标识
PubMed 42121898 · DOI 10.3390/cells15090797